Future directions for insulin therapy and diabetes treatment (Q37136651)

18 August 2017

1 reference

title

Future directions for insulin therapy and diabetes treatment (English)

1 reference

18 August 2017

1 reference

1

Lutz Heinemann

1 reference

18 August 2017

1 December 2007

1 reference

Endocrinology and Metabolism Clinics of North America

18 August 2017

1 reference

18 August 2017

36 Suppl 2

1 reference

18 August 2017

69-79

1 reference

Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050.

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

When oral agents fail: practical barriers to starting insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Concept, strategies, and feasibility of noninvasive insulin delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

1 reference

7 January 2021

Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Insulin glulisine: a faster onset of action compared with insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Will availability of inhaled human insulin (Exubera) improve management of type 2 diabetes? The design of the Real World trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Oral delivery of insulin with the eligen technology: mechanistic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Effects of intranasal insulin in non-obese type II diabetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Implantable insulin pumps. A position statement about their clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Are insulin pumps underutilized in type 1 diabetes? No.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

Are insulin pumps underutilized in type 1 diabetes? Yes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

OmniPod Insulin Management System: patient perceptions, preference, and glycemic control.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980012-0

7 January 2021

10.1016/S0889-8529(07)80012-0

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18407034